Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Contact Dermatitis. 2024 Aug;91(2):146-151. doi: 10.1111/cod.14594. Epub 2024 May 20.
Cutaneous manifestations of drug-induced type IV reactions vary widely, with symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) being a less common presentation. Corticosteroids (CS), primarily known for their anti-inflammatory effects, rarely induce hypersensitivity reactions.
The aim of this case series is to report four cases of SDRIFE following systemic prednisolone therapy and to review existing CS classification proposals to better understand cross-reactivity of CS.
PATIENTS/METHODS: Patients recruited at a German dermatology centre underwent allergologic evaluation including prick and patch testing with various CS. Positive cases underwent oral challenge testing with alternative agents. The classification systems of Coopman et al. and Baeck et al. were taken into account.
Despite a paucity of literature, CS-induced type IV reactions do occur, including SDRIFE. Classification systems based on chemical structure provide insight into cross-reactivity patterns. Provocation tests with alternative CS highlight the complexity of managing CS hypersensitivity.
SDRIFE may develop following systemic prednisolone therapy. Classification systems are helpful in understanding cross-reactivity and help in the selection of alternative preparations but are not always reliable. Individualised assessment is crucial for managing CS hypersensitivity, with consideration of alternative agents and emergency use of CS when necessary.
药物诱导的 IV 型反应的皮肤表现多种多样,对称性药物相关性间擦疹和褶皱部疹(SDRIFE)是一种不太常见的表现。皮质类固醇(CS)主要以其抗炎作用而闻名,很少引起过敏反应。
本病例系列报告了 4 例系统性泼尼松龙治疗后发生的 SDRIFE,并回顾了现有的 CS 分类建议,以更好地了解 CS 的交叉反应性。
患者/方法:在德国皮肤科中心招募的患者接受了过敏评估,包括各种 CS 的划痕和斑贴试验。阳性病例进行替代药物的口服激发试验。考虑了 Coopman 等人和 Baeck 等人的分类系统。
尽管文献很少,但确实会发生 CS 诱导的 IV 型反应,包括 SDRIFE。基于化学结构的分类系统提供了对交叉反应模式的深入了解。替代 CS 的激发试验突出了管理 CS 过敏反应的复杂性。
系统性泼尼松龙治疗后可能会发生 SDRIFE。分类系统有助于理解交叉反应性,并有助于替代制剂的选择,但并不总是可靠的。对于管理 CS 过敏反应,个体化评估至关重要,需要考虑替代药物,并在必要时紧急使用 CS。